Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
KRBP Suspended from Trading on Nasdaq
KRBP在納斯達克停牌
HOUSTON--(BUSINESS WIRE)--Sep. 13, 2023-- Kiromic BioPharma (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces that on September 12, 2023 it received formal notice from the NASDAQ Stock Market that the Company's common stock has been suspended from trading on the Nasdaq Capital Market effective September 14, 2023, due to failure to demonstrate compliance with Listing Rule 5550(b)(1).
休斯頓--(美國商業新聞網)--9月2023年13年--基羅米克生物製藥(納斯達克：KRBP)(“基羅米克”或“公司”)，一家臨床階段的完全集成的生物治療公司，使用其專有的鑽石致力於開發以免疫腫瘤學為重點的細胞療法的人工智慧和數據挖掘平臺宣佈，於2023年9月12日收到納斯達克股票市場正式通知，因未能證明符合上市規則第5550(B)(1)條，本公司普通股已於2023年9月14日在納斯達克資本市場停牌。
The Company's common stock will be quoted on the Pink Sheets platform operated by OTC Markets Group Inc. (the "OTC") and will commence trading on September 14, 2023 at the market open under the "KRBP" ticker symbol.
該公司的普通股將在場外交易市場集團(“OTC”)運營的粉單平臺上報價，並將於2023年9月14日在市場開盤時開始交易，股票代碼為“KRBP”。
The Company's stock will be quoted on the OTC Pink Open Market while it pursues an uplisting to the OTCQB exchange.
該公司的股票將在場外粉色市場報價公開市場，而它追求的是OTCQB交易所的升級。
Kiromic remains committed to maintaining transparency with its shareholders. While the reporting requirements are different on the OTC Pink Sheets, the Company will continue to file regular financial statements and provide updates consistent with Nasdaq requirements and past practices.
Kiroic仍致力於保持與股東的透明度。雖然場外粉表的報告要求有所不同，但公司將繼續定期提交財務報表，並提供符合納斯達克要求和過去做法的最新情況。
About Kiromic BioPharma
關於Kiroic BioPharma
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid cancers. Kiromic's DIAMONDAI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.
Kiroic BioPharma，Inc.是一家臨床階段的、完全集成的生物療法公司，使用其專利鑽石人工智慧(AI)2.0目標發現引擎開發細胞並將其商業化以免疫腫瘤學為重點的治療。Kiroic正在開發一種多適應症同種異體細胞治療平臺，該平臺利用Gamma Delta T細胞的自然效力來靶向實體癌症。基洛米奇鑽石人工智慧是數據科學與目標識別相結合的地方，可以極大地壓縮開發一種活藥物所需的數年和數億美元。該公司在德克薩斯州休斯敦設有辦事處。要了解更多資訊，請訪問Www.kiromic.com並在Twitter和LinkedIn上與我們聯繫。
Forward-Looking Statements
前瞻性陳述
This press release contains forward-looking statements that involve substantial risks and uncertainties. Kiromic makes such forward-looking statements pursuant to the safe harbor provisions of the United States Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as: "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding: Kiromic's ability to achieve its objectives and Kiromic's financing strategy and availability of funds. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in our Annual Report on Form 10-K for the year ended December 31, 2022, and as detailed from time to time in our other SEC filings. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Such forward-looking statements relate only to events as of the date of this press release. We undertake no obligation to update any forward-looking statements except to the extent required by law.
本新聞稿包含涉及重大風險和不確定因素的前瞻性陳述。基羅米奇根據《美國私人證券訴訟改革法》、修訂後的1934年《證券交易法》第21E條以及其他聯盟證券法中的安全港條款作出這樣的前瞻性陳述。除歷史事實以外的所有陳述均為前瞻性陳述。在某些情況下，您可以通過以下術語來識別前瞻性陳述：“將”、“潛在”、“可能”、“可以”、“相信”、“打算”、“繼續”、“計劃”、“預期”、“預期”、“估計”、“可能”或這些術語或其他類似術語的否定。這些前瞻性陳述包括但不限於有關Kiroic實現其目標的能力以及Kiroic的融資戰略和資金可獲得性的陳述。這些前瞻性表述涉及已知和未知的風險、不確定性和其他因素，可能導致實際結果、活動水準、業績或成就與這些前瞻性表述明示或暗示的資訊大不相同。這些風險和不確定性包括但不限於我們在截至2022年12月31日的10-K表格年度報告中討論的風險和不確定性，以及我們在提交給美國證券交易委員會的其他檔案中不時詳細介紹的那些風險和不確定性。你不應該依賴前瞻性陳述作為對未來事件的預測。儘管我們認為前瞻性陳述中反映的預期是合理的，但我們不能保證前瞻性陳述中反映的未來結果、活動水準、業績或事件和情況將會實現或發生。此外，我們或任何其他人都不對前瞻性陳述的準確性和完整性承擔責任。此類前瞻性陳述僅涉及截至本新聞稿發佈之日發生的事件。我們沒有義務更新任何前瞻性陳述，除非法律要求。
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913097444/en/
Kiromic BioPharma
Linda Phelan Dyson, MPH
Global Head, Corporate Communications
ldyson@kiromic.com
281-468-7683
Kiroic BioPharma
琳達·費蘭·戴森，最高時速
全球企業公關主管
郵箱：ldyson@kiromic.com
281-468-7683
LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614
LHA投資者關係
蒂爾思·T·帕特爾
郵箱：tpatel@lhai.com
212-201-6614
Source: Kiromic BioPharma
消息來源：Kiroic BioPharma